公开(公告)号：WO2017205766A1

公开(公告)日：2017-11-30

申请号：PCT/US2017/034721

申请日：2017-05-26

Applicant: PHARMACYCLICS LLC

Inventor： CHEN, Wei ,  JIA, Zhaozhong, J. ,  THOMAS, William, D. ,  WONE, David

IPC: C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are inhibitors of IRAK protein kinase of formula (I). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the IRAK inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract translation: 本文公开了式（I）的IRAK蛋白激酶的抑制剂。 还公开了包含该化合物的药物组合物。 单独或与其他治疗剂组合使用IRAK抑制剂的方法用于治疗自身免疫性疾病或病症，异质性免疫性疾病或病症，癌症（包括淋巴瘤和炎症性疾病或病症）。

公开(公告)号：WO2017205769A1

公开(公告)日：2017-11-30

申请号：PCT/US2017/034725

申请日：2017-05-26

Applicant: PHARMACYCLICS LLC

Inventor： CHEN, Wei ,  JIA, Zhaozhong, J. ,  THOMAS, William, D. ,  WONE, David

IPC: A61K31/519 ,  C07D471/04 ,  A61P35/00

Abstract: Disclosed herein are inhibitors of IRAK protein kinase of formula (I). Also disclosed are pharmaceutical compositions that include the compounds of formula (I). Methods of using the IRAK inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. Formula (I)

Abstract translation: 本文公开了式（I）的IRAK蛋白激酶的抑制剂。 还公开了包含式（I）化合物的药物组合物。 单独或与其他治疗剂组合使用IRAK抑制剂的方法用于治疗自身免疫性疾病或病症，异质性免疫性疾病或病症，癌症（包括淋巴瘤）和炎性疾病或病症。 公式（I）

公开(公告)号：WO2017205762A1

公开(公告)日：2017-11-30

申请号：PCT/US2017/034717

申请日：2017-05-26

Applicant: PHARMACYCLICS LLC

Inventor： CHEN, Wei ,  JIA, Zhaozhong, J. ,  THOMAS, William, D. ,  WONE, David

IPC: C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D493/04 ,  A61K31/519 ,  A61P35/00

Abstract: Disclosed herein are inhibitors of IRAK protein kinase. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the IRAK inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract translation: 本文公开了IRAK蛋白激酶的抑制剂。 还公开了包含该化合物的药物组合物。 单独或与其他治疗剂组合使用IRAK抑制剂的方法用于治疗自身免疫性疾病或病症，异质性免疫性疾病或病症，癌症（包括淋巴瘤和炎症性疾病或病症）。